Ignite Creation Date:
2025-12-25 @ 2:28 AM
Ignite Modification Date:
2026-01-08 @ 5:45 PM
Study NCT ID:
NCT01623934
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-10-18
First Post:
2012-06-18
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development
Sponsor:
Université de Sherbrooke
Organization:
Study Overview
Official Title:
Role of Adipokines in Glucose Regulation During Pregnancy and in Fetal Development
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GEN3G
Brief Summary:
This study includes 2 phases. During phase 1, pregnant women are followed over the course of pregnancy. The phase 2 is a follow-up of the mother-child dyad at 3, 5 and 10-12 year after delivery.
The purpose of this phase 1 is to :
* assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes;
* assess levels of maternal adipokines as determinants of development and fetal growth;
* determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns.
The purpose of this phase 2 is to:
* identify DNA methylation variations at birth that are predictive of childhood overweight/obesity.
* identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity.
* establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age).
* identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3, 5 and 10 years of age.
The purpose of this phase 1 is to :
* assess the contribution and interactions of adipokines in the development of insulin resistance during pregnancy and gestational diabetes;
* assess levels of maternal adipokines as determinants of development and fetal growth;
* determine the genetic variations that influence levels of adipokines and glucose regulation during pregnancy and in newborns.
The purpose of this phase 2 is to:
* identify DNA methylation variations at birth that are predictive of childhood overweight/obesity.
* identify maternal characteristics associated with DNA methylation variations predictive of childhood overweight/obesity.
* establish whether the loci predictive of childhood overweight/obesity at birth are still differentially methylated at 5 years of age (samples collected at 5 years of age).
* identify DNA methylation variations at birth that are predictive of childhood neurodevelopment problems at 3, 5 and 10 years of age.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?: